(Q44413384)

2 December 2017

title

Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients (English)

1 reference

Cardiology and cardiovascular medicine

2 December 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0003-3928(02)00183-X

26 December 2023

author name string

E. Aliot

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12710293

26 December 2023

L. De Roy

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12710293

26 December 2023

A. Capucci

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12710293

26 December 2023

J. Hernández

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12710293

26 December 2023

I. Denjoy

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12710293

26 December 2023

J. M. Lupoglazoff

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12710293

26 December 2023

P. Coumel

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12710293

26 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12710293

26 December 2023

publication date

1 February 2003

1 reference

full work available at URL

2 December 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

https://api.elsevier.com/content/article/PII:S000339280200183X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0003-3928(02)00183-X

https://api.elsevier.com/content/article/PII:S000339280200183X?httpAccept=text/plain

26 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0003-3928(02)00183-X

Annales de Cardiologie et d'Angeiologie

26 December 2023

published in

1 reference

2 December 2017

volume

52

1 reference

2 December 2017

issue

1

1 reference

2 December 2017

page(s)

34-40

1 reference

Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Summary of efficacy and safety of flecainide for supraventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Flecainide acetate for long-term prevention of paroxysmal supraventricular tachyarrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Oral flecainide for prophylaxis of paroxysmal atrial fibrillation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Mechanisms and risk factors for proarrhythmia with type Ia compared with Ic antiarrhythmic drug therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Experimental models of reentry, antiarrhythmic, and proarrhythmic actions of drugs. Complexities galore!

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Pharmacodynamics and side effects of flecainide acetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle. Implications for possible antiarrhythmic and proarrhythmic mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. The Flecainide Supraventricular Tachycardia Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Cibenzoline versus flecainide in the prevention of paroxysmal atrial arrhythmias: a double-blind randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: the United States experience. The Flecainide Supraventricular Tachyarrhythmia Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-3928%2802%2900183-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

1 reference

2 December 2017

1 reference